According to the institution’s post on Facebook, during the 14 days since the first injection, no adverse reactions were reported, as was verified by a systematic check-up carried out by the multidisciplinary team working on the clinical trial.

‘The main objective of the study in this group, made up of children from 12 to 18 years of age, is to evaluate the safety of the vaccine in minors,’ the post states.

On July 1, the Center for State Control of Medicines, Equipment and Medical Devices (CEDMED) authorized the CIGB to start the ‘Ismaelillo’ Pediatric Clinical Trial with the Abdala vaccine, and 24 days later the same agency approved Phase II for the process.

This stage does not involve patients who receive a placebo and includes some 592 children and young people, who receive Abdala’s three-dose scheme with a time gap of 14 days between each, (0-14-28 days).

jg/lcr/mgt/ghp